Open an account

INVO Fertility

IVF · NASDAQ

$0.6016+$0.0006 (+0.10%)TodayMarket closed ·
Prev close $0.601

About IVF

INVO Fertility, Inc. operates as a revenue-generating fertility business. The company is headquartered in Sarasota, Florida and currently employs 28 full-time employees. The company went IPO on 2008-11-11. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. The company focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. The company has two operational INVO Centers in the United States and one IVF clinic. The company is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.

Employees
28
Headquarters
Sarasota, Florida
Listed
Nov 11, 2008
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
invofertility.com

IVF key statistics

Market cap
2.87M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
146.88K
Volume
69.39K
Open price
$0.6102
High today
$0.6436
Low today
$0.60
52 Week high
$30.00
52 Week low
$0.51

INVO Fertility (IVF) at a glance

INVO Fertility (IVF) last traded at $0.6016, with a market cap of 2.87M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.60 and $0.6436. The current price is 0.3% above the day's low and 6.5% below its high.

Volume so far is 69.39K shares, below the average of 146.88K shares a day.

Over the past year INVO Fertility has ranged from $0.51 to $30.00, and now sits 0% of the way up that range.

INVO Fertility met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.66 per share against an estimate of -$0.707.

IVF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 6.6% on average.

  1. Q1 FY23: reported -$0.20 per share against an estimate of $0.00
  2. Q2 FY23: reported -$3.06 per share against an estimate of $0.00
  3. Q3 FY23: reported -$0.70 per share against an estimate of $0.00
  4. Q4 FY24: reported -$3,104.40 per share against an estimate of -$424.20
  5. Q3 FY25: reported -$0.77 per share against an estimate of -$0.0404
  6. Q4 FY25: reported -$196.81 per share against an estimate of -$2.78
  7. Q1 FY26: reported -$3.38 per share against an estimate of -$1.26
  8. Q2 FY26: reported -$0.66 per share against an estimate of -$0.707

IVF news

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Shivdeep Dhaliwal

    Nike, Meta Platforms, INVO Fertility, EyePoint Pharmaceuticals, and Micron: Why These 5 Stocks Are on Investors' Radars Today

  • Henry Khederian

    INVO Fertility Stock Surges Following Q2 Earnings Beat

  • Avi Kapoor

    Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August

  • Avi Kapoor

    Dow Falls 150 Points; NY Empire State Manufacturing Index Rises In August

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Kaustubh Bagalkote

    What's Going On With INVO Fertility Stock Monday?

Similar companies

Companies in the same industry as INVO Fertility

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.